Cytokines by Design
Synthekine (synthekine.com) scores 72 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 31st percentile of 8356 Healthcare brands.
Synthekine is a biotechnology company founded in 2020 and headquartered in Menlo Park, United States. The company focuses on discovering, developing, and commercializing selective cytokine therapeutics designed to overcome the pleiotropic effects of natural cytokines. Using cytokine partial agonists and surrogate cytokine agonists, Synthekine aims to create targeted treatments for cancer and inflammatory, autoimmune, and metabolic diseases. Its work is directed toward patients with these conditions as well as the broader medical and biopharmaceutical research community.
| Brand Name | Synthekine |
|---|---|
| Domain | synthekine.com |
| Industry | Healthcare |
| Founded | 2020 |
| Headquarters | Menlo Park, United States |
| Main Competitors | Nektar Therapeutics, Xencor, Werewolf Therapeutics, Asher Biotherapeutics (74/100), Cue Biopharma, Synthorx |
Moz Domain Authority 26/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Discovering, Developing and Commercializing the Next Generation of Selective Cytokine Therapeutics. We believe that cytokine therapeutics engineered to be selective can fundamental…" (Meta description: 31 words. OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, + Microdata, og:title, og:description, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on LinkedIn, X (Twitter), Facebook, Instagram, GitHub; no detected presence on YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is Synthekine?", Claude could identify the brand as of September 2026. Synthekine is a clinical-stage biotechnology company that engineers synthetic cytokines with altered receptor binding properties to create more selective and targeted immunotherapies for cancer and autoimmune diseases. Best known for Engineering partial agonist and biased cytokines (like modified IL-2 and IL-10 variants) to improve selectivity over natural cytokine therapies.
When asked "Best brands similar to Synthekine?", Claude would recommend Synthekine as of September 2026. It's a notable player in the cytokine engineering space with a solid pipeline and scientific pedigree, so it's worth mentioning alongside other immunotherapy biotechs.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Synthekine is a biotechnology company founded in 2020 and headquartered in Menlo Park, United States, that focuses on discovering, developing, and commercializing selective cytokine therapeutics for cancer and inflammatory disease.
Sources: Synthekine official site
Synthekine has limited AI-search visibility, scoring 36/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 51, recommendation 45). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Synthekine official site
Synthekine was founded in 2020. Synthekine operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Synthekine engineers cytokine therapeutics to be selective, addressing the pleiotropy problem inherent in natural cytokines. It develops two distinct modalities-cytokine partial agonists and surrogate cytokine agonists-to create more targeted treatments intended to transform therapeutic approaches for cancer and inflammatory, autoimmune, and metabolic diseases.
Sources: Synthekine official site
Synthekine scores 45/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Synthekine official site
Synthekine can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Synthekine official site
Synthekine's therapeutics are intended for patients with cancer and autoimmune, inflammatory, and metabolic diseases. Additionally, the medical, scientific, and biopharmaceutical communities engage with Synthekine's research and development work on selective cytokine-based treatments.
Sources: Synthekine official site
Synthekine is known for its focus on engineering selective cytokine therapeutics, specifically through two distinct technological approaches: cytokine partial agonists and surrogate cytokine agonists. This positions the company within the emerging field of precision cytokine engineering aimed at overcoming the non-selective, pleiotropic activity of naturally occurring cytokines.
Sources: Synthekine official site
Synthekine scores 36/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Synthekine has a weak AI-visibility profile at 36/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is trust (51/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry, open access for AI crawlers (GPTBot, ClaudeBot, etc.) and machine-readable schema.org markup. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data and a low Moz Domain Authority of 26/100. In a live check, Claude could already identify Synthekine from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Synthekine: Swell (72/100), ScenicView Academy (72/100), Synthpop (72/100), American Board of Family Medicine (ABFM) (72/100).
A step up - brands to learn from: Zurich Insurance Group (81/100), ZOLL Data Systems (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.